MMV partner GSK ranked first in the Access to Medicine Index – again

Index describes GSK as the most access-oriented company

17 Nov 2016

GSK has been ranked first in the Access to Medicine Index for the fifth consecutive time; taking a leadership position in research & development; pricing, manufacturing and distribution of medicines; and product donations.

2 billion people in the world have no access to essential medicines. The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies in term of their work to remedy this situation. The Index looks at how companies make medicines, vaccines and diagnostics more accessible in low and middle-income countries. GSK was found to be the most access-oriented company.

Commenting on the 2016 Index, GSK CEO Sir Andrew Witty said: “We are delighted that our commitments to widening access to the most possible patients have been recognised by the Access to Medicines Index for almost a decade. We have made fundamental changes to our business model so that it is founded on both innovation and access. But we cannot stand still. Getting medicines and vaccines to those who need them is a multi-faceted and evolving challenge; this year’s Index, which was tougher and more rigorous than ever, reflects this complexity. As a business, and an industry, we must push ourselves to go further and faster in strengthening access to healthcare.”

“We are proud to count GSK among our most long-standing partners and pleased to see their persistent efforts to advance equitable access to global healthcare recognised by the Index,” said Dr David Reddy, MMV’s CEO. “GSK and MMV have been partnering for more than a decade across all stages of the antimalarial drug development pipeline. One of our most exciting clinical development programmes targeting relapsing malaria is almost near completion and we look forward to continuing to work shoulder to shoulder with GSK to ensure that, if approved, the medicine will be accessed by vulnerable populations around the world.”